Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate an open, multi-center Phase Ib/II study. The study will assess the drug candidate HRS2398 in combination with HRS-1167 or adebrelimab (SHR-1316) or SHR-A1921 for the treatment of advanced solid tumors.
HRS2398 is an oral ATR inhibitor with a novel mechanism of action that exacerbates DNA double-strand damage, thereby inhibiting cell proliferation and demonstrating anti-tumor effects. This potential first-in-class product has no similar marketed equivalents globally. The study aims to explore the safety, tolerability, and preliminary efficacy of these combinations in patients with advanced solid tumors.
Adebrelimab, a programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb), has been approved in China for the first-line treatment of extensive stage small-cell lung cancer (ES-SCLC) in combination with chemotherapy since March of last year. The upcoming study represents a significant step in exploring the potential synergies of these drug combinations in tackling advanced solid tumors.
This clinical trial marks a significant advancement for Jiangsu Hengrui Medicine as it continues to expand its pipeline and contribute to the development of innovative cancer therapies.- Flcube.com
